IDH2 and neoplasm: Importantly, clinical trials of mutant IDH inhibitors have shown enhanced patient survival, but in most cases, this is associated with inhibition of tumor growth rather than tumor shrinkage.7–9 As a result, pretreatment information regarding tumor growth rate is required in order to assess the impact of treatment, and confirming drug action at the tumor site can be challenging.